Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of XNW3009 in Healthy Adults
NCT04040907Phase 1Completed
- Sponsor
- Evopoint Biosciences
- Start
- Nov 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in gout and hyperuricemia comparing XNW3009 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events and Clinically significant changes from baseline in physical examinations. Started Nov 2019; status: completed.
02
Drugs
xininurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04040907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040907.